Fact CheckerSign in

NCT07739888Not yet recruitingPhase 3

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Source: ClinicalTrials.gov · Last updated 31 Jul 2026

Brief summary (registry, in English)

This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in eligible patients who completed the double-blinded core part of CMAA868A2302 (ANT-010/NCT05712200)

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
2500 (estimated)
First submitted
28 Jul 2026
Start date
30 Dec 2027
Primary completion date
30 Dec 2030
Lead sponsor
Novartis Pharmaceuticals
NCT number
NCT07739888

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 2500
  • From 30 Dec 2027 to the primary completion date, 30 Dec 2030
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients who have a history or evidence of any clinically significant disorder, condition, or disease that in the investigator's opinion or Sponsor physician (if consulted), would put the participant at risk or interfere with the study participation
  • History of hypersensitivity to the study drug or its excipients, to drugs of similar chemical classes
  • Any medical or psychiatric condition which in the judgment of the Investigator either requires urgent medical intervention/hospitalization or may preclude patients from complying with study requirements for the duration of the study.
    • Other protocol defined Inclusion/Exclusion criteria may apply

Other

  • Patients meeting any exclusion criteria in the core part.

Who the study is looking for

  • Patients are able to provide written informed consent to enter the extension part.
  • Patients must be on study treatment at the time of EoT visit in the core part.

Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.